Claudia Eder1, Stefan Schenk2, Jana Trifinopoulos2, Büsra Külekci3, Melanie Kienzl4, Sabrina Schildböck2, Michael Ogon2. 1. Department of Spine Surgery, Spine Center, Orthopaedic Hospital Speising, Speisinger Str. 109, 1130, Vienna, Austria. Claudia.Eder@oss.at. 2. Department of Spine Surgery, Spine Center, Orthopaedic Hospital Speising, Speisinger Str. 109, 1130, Vienna, Austria. 3. University of Applied Sciences, Vienna, Austria. 4. Karl Franzens University Graz, Graz, Styria, Austria.
Abstract
PURPOSE: Surgical site infections represent a major complication of spinal surgery. The application of lyophilised vancomycin into the wound is reported to significantly decrease infection rates. As concentrations applied locally can exceed the minimal bacterial inhibitory concentration for more than a 1000-fold, toxic side effects on local tissue may be possible. METHODS: Primary osteoblast cell cultures were generated from bone tissue samples of 10 patients. Samples were incubated in absence or presence of either 3, 6 or 12 mg/cm(2) vancomycin according to a planned phase I clinical trial protocol. Changes in pH, osteoblast migration, proliferation and viability were analysed. Alkaline phosphatase as well as mineralisation patterns was studied. RESULTS: The application of more than 3 mg/cm(2) vancomycin induced a decline of pH. The migration potential of osteoblasts was decreased from 100% (control samples) to zero (12 mg/cm(2) vancomycin) in a dose-dependant manner. Cell proliferation was significantly inhibited at dosages above 3 mg/cm(2). Significant cell death was observed if the dosage applied exceeded 6 mg/cm(2). The synthesis of alkaline phosphatase was markedly reduced in all dosages applied and calcium deposition was significantly decreased in dosages above 3 mg/cm(2). CONCLUSION: As bone remodelling requires the immigration, proliferation and differentiation of osteoblasts at the fusion site, high dosages of intrawound vancomycin might interfere with regenerative processes and increase the risk of non-union. To allow an appropriate balance of infection risk and the risk of non-union, the minimal local concentration required should be determined by controlled in vivo studies.
PURPOSE: Surgical site infections represent a major complication of spinal surgery. The application of lyophilised vancomycin into the wound is reported to significantly decrease infection rates. As concentrations applied locally can exceed the minimal bacterial inhibitory concentration for more than a 1000-fold, toxic side effects on local tissue may be possible. METHODS: Primary osteoblast cell cultures were generated from bone tissue samples of 10 patients. Samples were incubated in absence or presence of either 3, 6 or 12 mg/cm(2) vancomycin according to a planned phase I clinical trial protocol. Changes in pH, osteoblast migration, proliferation and viability were analysed. Alkaline phosphatase as well as mineralisation patterns was studied. RESULTS: The application of more than 3 mg/cm(2) vancomycin induced a decline of pH. The migration potential of osteoblasts was decreased from 100% (control samples) to zero (12 mg/cm(2) vancomycin) in a dose-dependant manner. Cell proliferation was significantly inhibited at dosages above 3 mg/cm(2). Significant cell death was observed if the dosage applied exceeded 6 mg/cm(2). The synthesis of alkaline phosphatase was markedly reduced in all dosages applied and calcium deposition was significantly decreased in dosages above 3 mg/cm(2). CONCLUSION: As bone remodelling requires the immigration, proliferation and differentiation of osteoblasts at the fusion site, high dosages of intrawound vancomycin might interfere with regenerative processes and increase the risk of non-union. To allow an appropriate balance of infection risk and the risk of non-union, the minimal local concentration required should be determined by controlled in vivo studies.
Authors: Cyrus Caroom; Jessica M Tullar; E Garrison Benton; Jason R Jones; Christopher D Chaput Journal: Spine (Phila Pa 1976) Date: 2013-06-15 Impact factor: 3.468
Authors: Kevin R O'Neill; Jason G Smith; Amir M Abtahi; Kristin R Archer; Dan M Spengler; Matthew J McGirt; Clinton J Devin Journal: Spine J Date: 2011-05-19 Impact factor: 4.166
Authors: Battugs Borkhuu; Andrzej Borowski; Suken A Shah; Aaron G Littleton; Kirk W Dabney; Freeman Miller Journal: Spine (Phila Pa 1976) Date: 2008-10-01 Impact factor: 3.468
Authors: Itai Gans; John P Dormans; David A Spiegel; John M Flynn; Wudbhav N Sankar; Robert M Campbell; Keith D Baldwin Journal: Spine (Phila Pa 1976) Date: 2013-09-01 Impact factor: 3.468
Authors: Joshua M Pahys; Jenny R Pahys; Samuel K Cho; Matthew M Kang; Lukas P Zebala; Ammar H Hawasli; Fred A Sweet; Dong-Ho Lee; K Daniel Riew Journal: J Bone Joint Surg Am Date: 2013-03-20 Impact factor: 5.284
Authors: Ashok K Shyam; Parag K Sancheti; Salim K Patel; Steve Rocha; Chetan Pradhan; Atul Patil Journal: Indian J Orthop Date: 2009-10 Impact factor: 1.251
Authors: James X Liu; Dalibel Bravo; John Buza; Thorsten Kirsch; Oran Kennedy; Andrew Rokito; Joseph D Zuckerman; Mandeep S Virk Journal: J Orthop Date: 2018-01-30
Authors: Sravani Kondapavulur; John F Burke; Monica Volz; Doris D Wang; Philip A Starr Journal: Stereotact Funct Neurosurg Date: 2021-11-26 Impact factor: 1.875